BRPI1011306A2 - formulação adequada para injeção subcutânea, e, métodos para proporcionar redução cosmética de gordura de um humano, e para proporcionar uma redução cosmética da cintura de pelo menos dois centímetros em um humano - Google Patents
formulação adequada para injeção subcutânea, e, métodos para proporcionar redução cosmética de gordura de um humano, e para proporcionar uma redução cosmética da cintura de pelo menos dois centímetros em um humanoInfo
- Publication number
- BRPI1011306A2 BRPI1011306A2 BRPI1011306A BRPI1011306A BRPI1011306A2 BR PI1011306 A2 BRPI1011306 A2 BR PI1011306A2 BR PI1011306 A BRPI1011306 A BR PI1011306A BR PI1011306 A BRPI1011306 A BR PI1011306A BR PI1011306 A2 BRPI1011306 A2 BR PI1011306A2
- Authority
- BR
- Brazil
- Prior art keywords
- human
- providing
- cosmetic reduction
- centimeters
- waist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q90/00—Cosmetics or similar toiletry preparations for specific uses not provided for in other groups of this subclass
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Birds (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18162709P | 2009-05-27 | 2009-05-27 | |
| US25162409P | 2009-10-14 | 2009-10-14 | |
| US28997209P | 2009-12-23 | 2009-12-23 | |
| PCT/US2010/036484 WO2010138770A2 (en) | 2009-05-27 | 2010-05-27 | Methods for administration and formulations for the treatment of regional adipose tissue |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1011306A2 true BRPI1011306A2 (pt) | 2016-03-22 |
Family
ID=42371094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1011306A BRPI1011306A2 (pt) | 2009-05-27 | 2010-05-27 | formulação adequada para injeção subcutânea, e, métodos para proporcionar redução cosmética de gordura de um humano, e para proporcionar uma redução cosmética da cintura de pelo menos dois centímetros em um humano |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US9132084B2 (pt) |
| EP (1) | EP2435050A4 (pt) |
| JP (2) | JP5763624B2 (pt) |
| KR (1) | KR101419106B1 (pt) |
| CN (2) | CN102448467A (pt) |
| AU (1) | AU2010253864B2 (pt) |
| BR (1) | BRPI1011306A2 (pt) |
| CA (1) | CA2761744C (pt) |
| EA (1) | EA030314B1 (pt) |
| GB (1) | GB2470818B (pt) |
| IL (1) | IL216217A0 (pt) |
| MX (1) | MX2011012542A (pt) |
| SG (1) | SG176206A1 (pt) |
| WO (1) | WO2010138770A2 (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2384641T3 (es) | 2005-07-14 | 2012-07-10 | Lithera, Inc. | Formulación lipolítica que potencia la liberación mantenida para el tratamiento localizado del tejido adiposo |
| PL2077830T3 (pl) * | 2006-10-17 | 2013-04-30 | Lithera Inc | Sposoby, kompozycje i formulacje do leczenia orbitopatii tarczycowej |
| GB2436412A (en) * | 2006-11-27 | 2007-09-26 | Cvon Innovations Ltd | Authentication of network usage for use with message modifying apparatus |
| US9132084B2 (en) | 2009-05-27 | 2015-09-15 | Neothetics, Inc. | Methods for administration and formulations for the treatment of regional adipose tissue |
| BR112012017556A2 (pt) * | 2010-01-15 | 2016-08-16 | Lithera Inc | formulações de torta liofilizada |
| GB2485886A (en) * | 2010-11-24 | 2012-05-30 | Lithera Inc | Injectable formulations comprising a lipophilic glucocorticosteroid for regional adiposity reduction |
| GEP201606551B (en) * | 2010-11-24 | 2016-10-10 | Novamedica Llc | Selective, lipophilic, and long-acting beta agonists monotherapeutic formulations tions and methods for cosmetic treatment of adiposity and contour bulging |
| US20160089346A1 (en) * | 2014-09-25 | 2016-03-31 | Neothetics, Inc. | Method of treatment for body contouring |
| WO2016060564A1 (en) * | 2014-10-14 | 2016-04-21 | Brains Online Holding B.V. Et All | Body sculpting |
| TWI793165B (zh) | 2017-09-11 | 2023-02-21 | 美商阿托薩醫療公司 | 製造及使用因多昔芬(endoxifen)之方法 |
| US12201591B2 (en) | 2019-07-03 | 2025-01-21 | Atossa Therapeutics, Inc. | Sustained release compositions of endoxifen |
| GB202205895D0 (en) * | 2022-04-22 | 2022-06-08 | Atrogi Ab | New medical uses |
Family Cites Families (121)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3898330A (en) | 1973-08-01 | 1975-08-05 | Squibb & Sons Inc | Corticosteroid phosphate salts/neomycin sulfate ophthalmic |
| US4525359A (en) | 1982-12-10 | 1985-06-25 | Greenway Frank L Iii | Treatment for selective weight control |
| NZ212204A (en) | 1984-06-04 | 1988-07-28 | Merck & Co Inc | Growth-promoting compositions containing hydroxylic compounds |
| GB8426672D0 (en) | 1984-10-22 | 1984-11-28 | Erba Farmitalia | Pharmaceutical compositions |
| JPH0696521B2 (ja) | 1986-01-31 | 1994-11-30 | 千寿製薬株式会社 | 眼局所投与用眼圧降下剤 |
| FR2602423B1 (fr) | 1986-08-08 | 1989-05-05 | Ethypharm Sa | Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede |
| US5270305A (en) | 1989-09-08 | 1993-12-14 | Glaxo Group Limited | Medicaments |
| CA2030174C (en) | 1990-01-10 | 1996-12-24 | Anthony H. Cincotta | Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates |
| US5126147A (en) | 1990-02-08 | 1992-06-30 | Biosearch, Inc. | Sustained release dosage form |
| US5919827A (en) | 1990-07-11 | 1999-07-06 | Sepracor Inc. | Method for treating asthma using optically pure R(-) salmeterol |
| SE9302777D0 (sv) * | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
| US5658549A (en) | 1991-12-12 | 1997-08-19 | Glaxo Group Limited | Aerosol formulations containing propellant 134a and fluticasone propionate |
| SK282826B6 (sk) | 1991-12-18 | 2002-12-03 | Aktiebolaget Astra | Farmaceutická kompozícia na podávanie inhaláciou s obsahom formoterolu a budesonidu a jej použitie |
| AU675633B2 (en) | 1991-12-18 | 1997-02-13 | Minnesota Mining And Manufacturing Company | Suspension aerosol formulations |
| US5314916A (en) | 1993-04-19 | 1994-05-24 | Alcon Laboratories, Inc. | B2 adrenegic agonists and use thereof in the treatment of glaucoma |
| US6316443B1 (en) | 1994-08-04 | 2001-11-13 | Merck & Co., Inc. | Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a β-adrenergic antagonist |
| GB9512854D0 (en) | 1995-06-23 | 1995-08-23 | Wellcome Found | Novel formulation |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| AU4582797A (en) | 1996-09-13 | 1998-04-02 | Regents Of The University Of California, The | Methods for treatment of retinal diseases |
| ATE413415T1 (de) | 1996-09-19 | 2008-11-15 | Univ Michigan | Polymere enthaltend polysaccharide wie alginate oder modifizierte alginate |
| SE9700135D0 (sv) | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
| TW469832U (en) | 1997-03-14 | 2001-12-21 | Astra Ab | Inhalation device |
| CN1269722A (zh) | 1997-03-18 | 2000-10-11 | Basf公司 | 调节对皮质类固醇反应的方法及组合物 |
| US6656508B2 (en) | 1997-04-17 | 2003-12-02 | Amgen Inc. | Sustained-release alginate gels |
| WO1998048810A1 (en) | 1997-04-30 | 1998-11-05 | Bridge Pharma, Inc. | Composition and methods using an eutomer |
| US20010044584A1 (en) | 1997-08-28 | 2001-11-22 | Kensey Kenneth R. | In vivo delivery methods and compositions |
| SE9703407D0 (sv) | 1997-09-19 | 1997-09-19 | Astra Ab | New use |
| JPH11106334A (ja) | 1997-09-30 | 1999-04-20 | Saitama Daiichi Seiyaku Kk | 尿失禁治療剤 |
| JPH11106634A (ja) | 1997-09-30 | 1999-04-20 | Ge Plastics Japan Ltd | 芳香族ポリカーボネート樹脂組成物 |
| US20030095925A1 (en) | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders |
| US20040152664A1 (en) | 1998-09-02 | 2004-08-05 | Allergan, Inc. | Prednisolone compositions |
| US6384259B1 (en) | 1998-11-16 | 2002-05-07 | Medimmune Oncology, Inc. | Stable amorphous amifostine compositions and dosage form |
| WO2001019373A2 (en) | 1999-09-17 | 2001-03-22 | Basf Aktiengesellschaft | Methods and compositions for modulating responsiveness to corticosteroids |
| GB9924992D0 (en) | 1999-10-21 | 1999-12-22 | Glaxo Group Ltd | Pharmaceutical aerosol formulations |
| US6569903B2 (en) | 1999-12-07 | 2003-05-27 | Rohto Pharmaceutical Co., Ltd. | Ophthalmic compositions |
| US20040208910A1 (en) | 2000-04-26 | 2004-10-21 | Control Delivery Systems, Inc. | Sustained release device and method for ocular delivery of adrenergic agents |
| GB0012260D0 (en) | 2000-05-19 | 2000-07-12 | Astrazeneca Ab | Novel composition |
| AUPQ797700A0 (en) | 2000-06-06 | 2000-06-29 | Austin Research Institute, The | Vaccine |
| US6936426B2 (en) | 2000-10-06 | 2005-08-30 | Harbor-Ucla Research And Education Institute | Detection of antibody mediated inflammatory auto-immune disorders |
| FI20002216A0 (fi) | 2000-10-06 | 2000-10-06 | Orion Yhtymae Oyj | Yhdistelmäpartikkelit astman hoitoon |
| FI20002215A0 (fi) | 2000-10-06 | 2000-10-06 | Orion Yhtymae Oyj | Yhdistelmäpartikkelit |
| JP2004513340A (ja) | 2000-11-03 | 2004-04-30 | ヒストオテック エーピーエス | 組織ブロックを切片化するための装置および方法 |
| ES2260321T3 (es) | 2000-12-07 | 2006-11-01 | Universiteit Utrecht Holding B.V. | Composicion para el tratamiento de transtornos inflamatorios. |
| US20030022856A1 (en) | 2001-01-30 | 2003-01-30 | The Regents Of The University Of Michigan | Method for sustained release local delivery of drugs for ablation of unwanted tissue |
| UA77656C2 (en) | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
| US20030055026A1 (en) | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
| MY137522A (en) | 2001-04-30 | 2009-02-27 | Glaxo Group Ltd | Novel anti-inflammatory androstane derivatives. |
| US6726714B2 (en) * | 2001-08-09 | 2004-04-27 | Scimed Life Systems, Inc. | Stent delivery system |
| GB0124523D0 (en) | 2001-10-12 | 2001-12-05 | Glaxo Group Ltd | Pharmaceutical combination |
| JP2005508220A (ja) | 2001-10-24 | 2005-03-31 | パーリ・ゲーエムベーハー | 薬用組成物調製用具 |
| US6625078B2 (en) | 2002-02-11 | 2003-09-23 | United Memories, Inc. | Look-ahead refresh for an integrated circuit memory |
| US8541399B2 (en) | 2002-02-19 | 2013-09-24 | Resolution Chemicals Limited | Solvent-based sterilisation of pharmaceuticals |
| US20050009798A1 (en) | 2002-02-20 | 2005-01-13 | Sepracor Inc. | Carbonate and carbamate modified forms of glucocorticoids in combination with B2 adrenergic agonists |
| US7140371B2 (en) | 2002-03-14 | 2006-11-28 | Allergan, Inc. | Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins |
| US6688311B2 (en) | 2002-03-14 | 2004-02-10 | Allergan, Inc. | Method for determining effect of a clostridial toxin upon a muscle |
| US6643212B1 (en) | 2002-04-18 | 2003-11-04 | United Memories, Inc. | Simultaneous function dynamic random access memory device technique |
| US20040028545A1 (en) | 2002-08-06 | 2004-02-12 | Ta-Chin Wang | Cylinder assembly for a mini air compressor |
| AU2003263717A1 (en) | 2002-09-25 | 2004-04-19 | Astrazeneca Ab | A COMBINATION OF A LONG-ACTING Beta2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES |
| CA2500065A1 (en) | 2002-09-30 | 2004-04-15 | Acusphere, Inc. | Sustained release porous microparticles for inhalation |
| US20040208833A1 (en) | 2003-02-04 | 2004-10-21 | Elan Pharma International Ltd. | Novel fluticasone formulations |
| EP1613266A4 (en) | 2003-04-15 | 2009-05-06 | Theraquest Biosciences Llc | METHOD FOR TREATING PAIN AND COMPOSITIONS FOR USE THEREOF |
| US9808471B2 (en) | 2003-04-16 | 2017-11-07 | Mylan Specialty Lp | Nasal pharmaceutical formulations and methods of using the same |
| JP4103672B2 (ja) * | 2003-04-28 | 2008-06-18 | 株式会社村田製作所 | 導電性ペーストおよびガラス回路構造物 |
| WO2004103057A2 (en) * | 2003-05-15 | 2004-12-02 | The University Of Georgia Research Foundation, Inc. | Compositions and methods for inducing adipose tissue cell death |
| EP1635844A1 (en) | 2003-05-22 | 2006-03-22 | ALTANA Pharma AG | Salmeterol and ciclesonide combination |
| SE0302029D0 (sv) | 2003-07-07 | 2003-07-07 | Astrazeneca Ab | Novel process |
| TWI359675B (en) | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
| GB0316290D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
| GB2403655A (en) | 2003-07-11 | 2005-01-12 | Cipla Ltd | Combined pharmaceutical product comprising a beta-2 adrenoreceptor agonist & an antihistamine for treatment of respiratory diseases such as asthma |
| JP2007508240A (ja) | 2003-07-22 | 2007-04-05 | バクスター・インターナショナル・インコーポレイテッド | 低分子量有機分子の小球状粒子ならびにその調製方法および使用方法 |
| BRPI0414907A (pt) | 2003-09-30 | 2006-11-07 | Acusphere Inc | formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas |
| US20050075900A1 (en) | 2003-10-02 | 2005-04-07 | Arguimbau Vincent C. | Method and apparatus for bulk food marking and tracking with supplier rating system |
| DE10347994A1 (de) | 2003-10-15 | 2005-06-16 | Pari GmbH Spezialisten für effektive Inhalation | Wässrige Aerosol-Zubereitung |
| US20050089555A1 (en) | 2003-10-24 | 2005-04-28 | Aventis Pharma Deutschland Gmbh | Medicinal targeted local lipolysis |
| CN105820160B (zh) | 2003-11-05 | 2019-02-12 | 萨可德生物科学公司 | 细胞粘着调节剂 |
| ATE552838T1 (de) | 2003-11-14 | 2012-04-15 | Senju Pharma Co | Wässrige lösung mit aminoglykosid-antibiotikum und bromfenac |
| AU2004292416B2 (en) | 2003-11-20 | 2010-01-28 | Alteragon Pty Ltd | Method of decreasing fat deposits and body weight in mammals and birds |
| KR100573828B1 (ko) | 2003-12-29 | 2006-04-26 | 주식회사 하이닉스반도체 | 셀데이터의 손실을 방지하기 위한 반도체 메모리 소자 |
| US20080270175A1 (en) | 2003-12-31 | 2008-10-30 | Klinger Advanced Aesthetics, Inc. | Systems and methods using a dynamic expert system to provide patients with aesthetic improvement procedures |
| CN1640390A (zh) | 2004-01-17 | 2005-07-20 | 北京博尔达生物技术开发有限公司 | 注射用新鱼腥草素钠冻干粉针剂及制备方法 |
| US20050212152A1 (en) | 2004-03-23 | 2005-09-29 | Reens Daniel J | System and method for humidifying homes and commercial sites |
| US7754230B2 (en) | 2004-05-19 | 2010-07-13 | The Regents Of The University Of California | Methods and related compositions for reduction of fat |
| WO2006086001A2 (en) | 2004-07-20 | 2006-08-17 | Allergan, Inc. | Thermographic assessment of clostridial toxin applications |
| US7317023B2 (en) | 2004-07-21 | 2008-01-08 | Theravance, Inc. | Diaryl ether β2 adrenergic receptor agonists |
| EP1819318A1 (en) | 2004-11-24 | 2007-08-22 | Seo Hong Yoo | Dried forms of aqueous solubilized bile acid dosage formulation |
| EP1867334A4 (en) | 2005-02-18 | 2009-07-15 | Santen Pharmaceutical Co Ltd | METHOD FOR RELIEVING OR AVOIDING A SECONDARY EFFECT OF A STEROID COMPOUND |
| WO2006108176A2 (en) | 2005-04-08 | 2006-10-12 | The Regents Of The University Of California | Wound healing composition |
| US7931909B2 (en) | 2005-05-10 | 2011-04-26 | Allergan, Inc. | Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates |
| CN1706501A (zh) | 2005-05-27 | 2005-12-14 | 沈阳药科大学 | 亲脂性药物环糊精包合物的制备方法 |
| ES2384641T3 (es) | 2005-07-14 | 2012-07-10 | Lithera, Inc. | Formulación lipolítica que potencia la liberación mantenida para el tratamiento localizado del tejido adiposo |
| CN101252842A (zh) * | 2005-07-14 | 2008-08-27 | 利波西拉公司 | 用于局部脂肪组织治疗的持续释放的增强性脂肪分解性制剂 |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| FR2893845B1 (fr) | 2005-11-30 | 2010-10-29 | Galderma Sa | Composition sous forme de spray comprenant un corticoide et une phase huileuse |
| EP1973523A2 (en) | 2005-12-15 | 2008-10-01 | Acusphere, Inc. | Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration |
| US20070178051A1 (en) | 2006-01-27 | 2007-08-02 | Elan Pharma International, Ltd. | Sterilized nanoparticulate glucocorticosteroid formulations |
| WO2007111806A2 (en) | 2006-03-23 | 2007-10-04 | Massachusetts Eye And Ear Infirmary | Cyclopentane heptanoic acid compounds for reducing body fat |
| JP2009532489A (ja) | 2006-04-03 | 2009-09-10 | テバ ファーマシューティカル インダストリーズ リミティド | 薬剤微粒子 |
| DE102007026979A1 (de) | 2006-10-06 | 2008-04-10 | Friedrich Siller | Inhalationsvorrichtung |
| PL2077830T3 (pl) | 2006-10-17 | 2013-04-30 | Lithera Inc | Sposoby, kompozycje i formulacje do leczenia orbitopatii tarczycowej |
| US20100063006A1 (en) | 2006-11-22 | 2010-03-11 | American Network Of Lipolysis, Llc | Compositions and methods to reduce fat and retract skin |
| WO2008122118A1 (en) | 2007-04-04 | 2008-10-16 | Theratechnologies Inc. | Pharmaceutical formulations of ghrh molecules |
| US20090208492A1 (en) | 2007-06-14 | 2009-08-20 | Elan Pharmaceuticals, Inc. | Lyophilized Immunoglobulin Formulations and Methods of Preparation |
| SI2170348T1 (sl) | 2007-06-22 | 2016-12-30 | Dompe Farmaceutici S.P.A. | Šumeče tablete za inhalacijsko uporabo |
| US20090131386A1 (en) | 2007-11-13 | 2009-05-21 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
| WO2009073051A1 (en) | 2007-12-03 | 2009-06-11 | Bridge Pharma, Inc. | Use of rr/sr-ractopamine |
| US20130060123A1 (en) | 2008-01-09 | 2013-03-07 | Allergan, Inc. | Method for determining breast volume to assist medical procedure |
| US20120169732A1 (en) | 2008-01-09 | 2012-07-05 | Allergan, Inc. | Method for analysis of facial appearance to assist medical procedure |
| KR101184869B1 (ko) | 2008-04-24 | 2012-09-20 | 이매틱스 바이오테크놀로지스 게엠베하 | 백신을 위한 인간 조직 적합성 항원(ｈｌａ) 종류 ｉ 또는 ｉｉ 분자에 결합하는 종양 관련 펩티드의 신규한 제형 |
| US20110276135A1 (en) | 2008-10-17 | 2011-11-10 | Allergan, Inc. | Prosthetic implant shell |
| US20110230964A1 (en) | 2008-10-17 | 2011-09-22 | Allergan, Inc. | Prosthetic implant shell |
| US8101593B2 (en) | 2009-03-03 | 2012-01-24 | Kythera Biopharmaceuticals, Inc. | Formulations of deoxycholic acid and salts thereof |
| US9132084B2 (en) | 2009-05-27 | 2015-09-15 | Neothetics, Inc. | Methods for administration and formulations for the treatment of regional adipose tissue |
| BR112012017556A2 (pt) | 2010-01-15 | 2016-08-16 | Lithera Inc | formulações de torta liofilizada |
| GEP201606551B (en) | 2010-11-24 | 2016-10-10 | Novamedica Llc | Selective, lipophilic, and long-acting beta agonists monotherapeutic formulations tions and methods for cosmetic treatment of adiposity and contour bulging |
| EP3378480A1 (en) | 2011-01-19 | 2018-09-26 | Topokine Therapeutics, Inc. | Methods and compositions for treating obesity |
| CA2827643C (en) | 2011-02-18 | 2019-05-07 | Kythera Biopharmaceuticals, Inc. | Treatment of submental fat |
| US8653058B2 (en) | 2011-04-05 | 2014-02-18 | Kythera Biopharmaceuticals, Inc. | Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits |
| US8426471B1 (en) | 2011-12-19 | 2013-04-23 | Topokine Therapeutics, Inc. | Methods and compositions for reducing body fat and adipocytes |
| US20140094662A1 (en) | 2012-10-03 | 2014-04-03 | Allergan, Inc. | Method of assessing capsular formation and/or contracture |
| WO2014055895A1 (en) | 2012-10-05 | 2014-04-10 | Allergan, Inc. | Injectable device and method for sculpting, augmenting or correcting facial features such as the chin |
| CN104936595A (zh) | 2012-11-21 | 2015-09-23 | 托普凯恩制药公司 | 局部增加体脂肪的方法和组合物 |
-
2010
- 2010-05-26 US US12/788,190 patent/US9132084B2/en not_active Expired - Fee Related
- 2010-05-27 KR KR1020117031166A patent/KR101419106B1/ko not_active Expired - Fee Related
- 2010-05-27 CN CN2010800232776A patent/CN102448467A/zh active Pending
- 2010-05-27 CN CN201610945675.2A patent/CN106890334A/zh active Pending
- 2010-05-27 WO PCT/US2010/036484 patent/WO2010138770A2/en not_active Ceased
- 2010-05-27 EA EA201101565A patent/EA030314B1/ru not_active IP Right Cessation
- 2010-05-27 EP EP10781245.5A patent/EP2435050A4/en not_active Withdrawn
- 2010-05-27 SG SG2011086527A patent/SG176206A1/en unknown
- 2010-05-27 BR BRPI1011306A patent/BRPI1011306A2/pt not_active IP Right Cessation
- 2010-05-27 AU AU2010253864A patent/AU2010253864B2/en not_active Ceased
- 2010-05-27 JP JP2012513273A patent/JP5763624B2/ja not_active Expired - Fee Related
- 2010-05-27 MX MX2011012542A patent/MX2011012542A/es active IP Right Grant
- 2010-05-27 CA CA2761744A patent/CA2761744C/en not_active Expired - Fee Related
- 2010-05-27 GB GB1008885.4A patent/GB2470818B/en not_active Expired - Fee Related
-
2011
- 2011-10-28 US US13/284,741 patent/US8404750B2/en not_active Expired - Fee Related
- 2011-11-08 IL IL216217A patent/IL216217A0/en unknown
-
2014
- 2014-03-17 JP JP2014052975A patent/JP6078213B2/ja not_active Expired - Fee Related
-
2015
- 2015-07-29 US US14/812,993 patent/US9452132B2/en not_active Expired - Fee Related
-
2016
- 2016-05-16 US US15/156,187 patent/US20160256418A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20150328146A1 (en) | 2015-11-19 |
| JP6078213B2 (ja) | 2017-02-08 |
| IL216217A0 (en) | 2012-01-31 |
| KR101419106B1 (ko) | 2014-07-16 |
| CA2761744C (en) | 2016-01-05 |
| EP2435050A4 (en) | 2014-02-26 |
| US20120046257A1 (en) | 2012-02-23 |
| SG176206A1 (en) | 2011-12-29 |
| MX2011012542A (es) | 2011-12-14 |
| GB2470818B (en) | 2013-06-05 |
| GB2470818A (en) | 2010-12-08 |
| US8404750B2 (en) | 2013-03-26 |
| JP5763624B2 (ja) | 2015-08-12 |
| EA201101565A1 (ru) | 2012-06-29 |
| EA030314B1 (ru) | 2018-07-31 |
| AU2010253864A1 (en) | 2011-12-08 |
| EP2435050A2 (en) | 2012-04-04 |
| CN106890334A (zh) | 2017-06-27 |
| US20160256418A1 (en) | 2016-09-08 |
| CA2761744A1 (en) | 2010-12-02 |
| KR20140014404A (ko) | 2014-02-06 |
| WO2010138770A3 (en) | 2011-04-28 |
| WO2010138770A2 (en) | 2010-12-02 |
| US20110130373A1 (en) | 2011-06-02 |
| JP2014139211A (ja) | 2014-07-31 |
| JP2012528193A (ja) | 2012-11-12 |
| GB201008885D0 (en) | 2010-07-14 |
| CN102448467A (zh) | 2012-05-09 |
| US9452132B2 (en) | 2016-09-27 |
| AU2010253864B2 (en) | 2013-11-28 |
| US9132084B2 (en) | 2015-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1011306A2 (pt) | formulação adequada para injeção subcutânea, e, métodos para proporcionar redução cosmética de gordura de um humano, e para proporcionar uma redução cosmética da cintura de pelo menos dois centímetros em um humano | |
| IL238432B (en) | Methods and devices for the treatment of eye diseases in humans | |
| BR112014010186A2 (pt) | formulação farmacêutica estável, kit, composição farmacêutica, método para preparar uma formulação farmacêutica, e, método para tratar um humano ou animal | |
| PL2758381T3 (pl) | PREPARATY KOSMETYCZNE LUB DERMATOLOGICZNE ZAWIERAJĄCE AMIDOTIAZOLE ALKILOWE I ICH STOSOWANIE W CELU USUWANIA NIEPOŻĄDANYCH PRZEBARWIEŃ SKÓRY i ZAPOBIEGANIA ICH POWSTAWANIU | |
| BR112012008854A2 (pt) | combinação, kit de combinação, uso de uma combinação, composição farmacêutica, e, método para tratar câncer em um ser humano | |
| BR112012029746A2 (pt) | composição para tratamento da pele, método para fornecer um efeito microbicida para pele e uso de uma combinação | |
| PL2640352T3 (pl) | Hydrolizat kolagenu do zastosowania do poprawy zdrowia ludzkiej skóry, włosów i/lub paznokci | |
| ZA201400616B (en) | Methods and devices for drug delivery to ocular tissue using microneedle | |
| PL2911754T3 (pl) | Medyczny zestaw do podparcia nogi przystosowany do zwiększenia zakresu ruchu nogi w celu wspomagania gojenia i wzmocnienia uszkodzonej, zranionej i/lub wymienionej kości, mięśnia i/lub tkanki nogi | |
| IL226495A (en) | Derivatives of the Terroylsulfonamides, their preparation and their application in human therapy | |
| BRPI1011316A2 (pt) | aparelho e método para administrar uma substância ao tecido da pele, método para tratar um indivíduo tendo uma condição de pele, e, kit | |
| PH12013500876A1 (en) | Composition comprising hydrolysed proteins and oligosaccharides for treating skin diseases | |
| ZA201307641B (en) | Human tissue factor antibody and uses thereof | |
| PT2991479T (pt) | Dispositivo médico destinado à conservação a longo prazo de uma córnea, ou à experimentação ex vivo em córnea humana ou animal | |
| EP2493483A4 (en) | TOPICAL SKIN TREATMENT FORMULATION FOR ROSACEA AND CORRESPONDING METHOD | |
| PL2758383T3 (pl) | Preparaty kosmetyczne lub dermatologiczne zawierające amidotiazole aromatyczne i ich stosowanie do usuwania niepożądanych przebarwień skóry i zapobiegania ich powstawaniu | |
| LT2400943T (lt) | Kosmetinė arba farmacinė emulsija odai, sumaišytina prieš pat naudojimą | |
| EP2700654A4 (en) | HUMAN INSULIN AND ANALOG CONJUGATE THEREOF | |
| BR112014028878A2 (pt) | composição cosmética, método de tratamento cosmético da pele e uso de uma composição cosmética | |
| IL232402A0 (en) | Progenitors of human skeletal muscle brown fat cells | |
| PL2758382T3 (pl) | Preparaty kosmetyczne lub dermatologiczne zawierające aminotiazole heterocyklokarbonylowe i ich stosowanie do usuwania niepożądanych przebarwień skóry i zapobiegania ich powstawaniu | |
| BR112015006848A2 (pt) | formulação farmacêutica, método de indução de perda de peso, método de redução de gordura corporal, método de redução de ingesta de comida, método para melhorar homeostase de glicose e método para prevenir um aumento do índice de massa corporal de um paciente normal, pré-obeso, obeso ou obeso mórbido. | |
| IL238857A0 (en) | Absorbent and reflective biocompatible dyes for highly accurate medical implants | |
| FR2958935B1 (fr) | Derives d'heterocycles azotes, leur preparation et leur application en therapeutique humaine | |
| FR2954943B1 (fr) | Derives de pyridino-pyridinones arylsulfonamides, leur preparation et leur application en therapeutique |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: NEOTHETICS, INC. (US) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] | ||
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2516 DE 26-03-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |